|
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) Évaluation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) Bundle
Vous cherchez à évaluer la valeur intrinsèque de Heilongjiang ZBD Pharmaceutical Co., Ltd.? Notre calculatrice DCF (603567SS) intègre des données réelles avec des fonctionnalités de personnalisation complètes, vous permettant d'affiner vos projections et d'améliorer vos choix d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,296.8 | 3,410.9 | 4,130.0 | 4,219.4 | 3,143.5 | 3,153.0 | 3,162.6 | 3,172.1 | 3,181.7 | 3,191.4 |
| Revenue Growth, % | 0 | 3.46 | 21.08 | 2.17 | -25.5 | 0.30252 | 0.30252 | 0.30252 | 0.30252 | 0.30252 |
| EBITDA | 813.6 | 842.8 | 736.6 | 606.2 | 840.9 | 683.2 | 685.3 | 687.3 | 689.4 | 691.5 |
| EBITDA, % | 24.68 | 24.71 | 17.84 | 14.37 | 26.75 | 21.67 | 21.67 | 21.67 | 21.67 | 21.67 |
| Depreciation | 157.8 | 177.6 | 154.9 | 181.2 | 201.2 | 154.1 | 154.6 | 155.0 | 155.5 | 156.0 |
| Depreciation, % | 4.79 | 5.21 | 3.75 | 4.29 | 6.4 | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
| EBIT | 655.8 | 665.2 | 581.8 | 425.0 | 639.7 | 529.1 | 530.7 | 532.3 | 533.9 | 535.5 |
| EBIT, % | 19.89 | 19.5 | 14.09 | 10.07 | 20.35 | 16.78 | 16.78 | 16.78 | 16.78 | 16.78 |
| Total Cash | 2,553.8 | 1,539.0 | 1,551.2 | 1,001.9 | 1,454.5 | 1,451.4 | 1,455.8 | 1,460.2 | 1,464.6 | 1,469.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2,165.5 | 2,653.8 | 3,369.3 | 3,041.3 | 2,524.7 | 2,380.3 | 2,387.5 | 2,394.7 | 2,402.0 | 2,409.2 |
| Account Receivables, % | 65.68 | 77.8 | 81.58 | 72.08 | 80.31 | 75.49 | 75.49 | 75.49 | 75.49 | 75.49 |
| Inventories | 720.3 | 959.5 | 733.3 | 1,005.8 | 720.9 | 722.1 | 724.3 | 726.5 | 728.6 | 730.9 |
| Inventories, % | 21.85 | 28.13 | 17.75 | 23.84 | 22.93 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 |
| Accounts Payable | 249.7 | 581.3 | 797.0 | 806.2 | 333.0 | 464.2 | 465.6 | 467.0 | 468.4 | 469.9 |
| Accounts Payable, % | 7.57 | 17.04 | 19.3 | 19.11 | 10.59 | 14.72 | 14.72 | 14.72 | 14.72 | 14.72 |
| Capital Expenditure | -178.8 | -868.6 | -448.6 | -404.3 | -95.1 | -342.8 | -343.8 | -344.9 | -345.9 | -347.0 |
| Capital Expenditure, % | -5.42 | -25.47 | -10.86 | -9.58 | -3.03 | -10.87 | -10.87 | -10.87 | -10.87 | -10.87 |
| Tax Rate, % | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
| EBITAT | 498.7 | 540.2 | 424.9 | 264.0 | 632.2 | 414.0 | 415.3 | 416.5 | 417.8 | 419.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,158.4 | -546.8 | -142.5 | 105.7 | 1,066.5 | 499.7 | 218.0 | 218.7 | 219.3 | 220.0 |
| WACC, % | 4.87 | 4.92 | 4.84 | 4.73 | 5.1 | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,218.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 229 | |||||||||
| Terminal Value | 25,628 | |||||||||
| Present Terminal Value | 20,183 | |||||||||
| Enterprise Value | 21,402 | |||||||||
| Net Debt | 1,697 | |||||||||
| Equity Value | 19,705 | |||||||||
| Diluted Shares Outstanding, MM | 940 | |||||||||
| Equity Value Per Share | 20.96 |
Benefits You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-populated financial data for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- Accurate Data: Access to historical financial information and future projections (highlighted in the yellow cells).
- Adjustable Forecasts: Modify key assumptions such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly observe how changes in your inputs affect the valuation of Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Interface: Organized for straightforward navigation and usability, complete with comprehensive instructions.
Key Features
- Comprehensive DCF Calculator: Offers in-depth unlevered and levered DCF valuation models tailored for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- WACC Calculator: Features a pre-structured Weighted Average Cost of Capital sheet with adjustable input options.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- Interactive Dashboard and Charts: Visual representations distill essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the ready-to-use Excel template featuring Heilongjiang ZBD Pharmaceutical Co., Ltd.'s data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Adjust forecasts and assumptions in the editable yellow cells (WACC, growth rates, margins).
- Step 4: Immediately see the recalculated results, including the intrinsic value of Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- Step 5: Make well-informed investment decisions or create reports using the generated outputs.
Why Choose Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS)?
- Save Time: Skip the hassle of building complex financial models—ours is ready for immediate use.
- Enhance Accuracy: Dependable financial data and precise formulas minimize valuation errors.
- Completely Customizable: Modify the model to align with your specific assumptions and forecasts.
- User-Friendly Analysis: Intuitive charts and outputs make results straightforward to interpret.
- Recognized by Experts: Crafted for professionals who prioritize accuracy and functionality.
Who Can Benefit from This Product?
- Individual Investors: Make well-informed decisions regarding the purchase or sale of Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS) stock.
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for ZBD Pharmaceuticals.
- Consultants: Provide accurate and timely valuation insights to clients focusing on the pharmaceutical sector.
- Business Owners: Gain insights into the valuation of major players like Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS) to inform your own business strategies.
- Finance Students: Master valuation techniques by analyzing real-world data and case studies from Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
Contents of the Template
- Historical Data: Comprises Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (603567SS) previous financial records and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates designed for calculating the intrinsic value of Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567SS).
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust essential parameters such as growth rates, EBITDA percentages, and CAPEX forecasts.
- Quarterly and Annual Statements: A thorough analysis of Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (603567SS) financial statements.
- Interactive Dashboard: Dynamically visualize valuation results and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.